Concepedia

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen,

New England Journal of Medicine · 2019 · 1.9K citations · 21 references

DOIFull text

Open access

Concepts

Abstract

Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.

References

21

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

, , +15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

, , +17

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text

, , +13

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text

, , +17

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies, David A. D’Alessio, Judith Fradkin et al. · Diabetes Care · 2018 · 3.5K citations · Full text

, , +17